Vertex Pharma (VRTX) Announces EC Approval for KAFTRIO in Combination With Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older
Go back to Vertex Pharma (VRTX) Announces EC Approval for KAFTRIO in Combination With Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 496.50 -1.93 (0.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $498.43 | 52 Week High | $134.71 | |||
| Open | $495.58 | 52 Week Low | $73.31 | |||
| Day High | $500.77 | P/E | N/A | |||
| Day Low | $482.11 | EPS | $-1.98 | |||
| Volume | 2,107,187 | |||||
